Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate + ondansetron
- Development stage
- Phase 1
- Lead developer
- Generys Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methylphenidate + ondansetron (also known as OND-PR002 or MPh-IR + Ond-PR2) is an investigational fixed-dose combination of the central nervous system stimulant methylphenidate and the selective 5-HT3 serotonin receptor antagonist ondansetron. Developed by Duke University and its spinout Generys Biopharmaceuticals, the combination is designed to treat substance use disorders (such as cocaine and methamphetamine use disorders) and trauma- and stressor-related disorders. The therapeutic strategy relies on 'pharmacologically-mediated reactivation and reconsolidation blockade' of dysfunctional neural memories underlying addiction. The formulation combines immediate-release methylphenidate (acting as a dopamine and norepinephrine reuptake inhibitor to reactivate the drug memory) with a delayed pulsatile-release formulation of ondansetron (to block memory reconsolidation). It has been evaluated in Phase IIa clinical trials.
- Other names
- methylphenidate and ondansetronmethylphenidate hydrochloride + ondansetron hydrochloride
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate + ondansetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate + ondansetron.